  See all
 |
Articles: Myeloproliferative Dz |
Prior Articles
Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma
Expert Review of Anticancer Therapy, 07/13/09
NKG2D-mediated immunity underlying paroxysmal nocturnal haemoglobinuria and related bone marrow failure syndromes
British Journal of Haematology, 07/09/09
Exclusive Author Commentary The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes
Cancer, 07/07/09 Long-term outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
Blood, 07/02/09 Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996)
Blood, 07/02/09 Analysis of the Ten-Eleven Translocation (TET)2 gene in familial myeloproliferative neoplasms
Blood, 07/02/09 Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial
Leukemia and Lymphoma, 07/01/09 Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide, lenalidomide or bortezomib- containing regimens
Blood, 06/29/09 Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study
Haematologica, 06/26/09
Free full text
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometric in myelodysplastic syndromes
Haematologica, 06/26/09
Free full text
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
Blood, 06/24/09 Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature
Leukemia Research, 06/19/09 The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: A prospective study
Leukemia Research, 06/19/09 Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes
Leukemia Research, 06/19/09 Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome
Leukemia Research, 06/19/09 Impact on survival of different treatments for myelodysplastic syndromes (MDS)
Leukemia Research, 06/19/09 A myeloproliferative disorder may hide another one
Leukemia Research, 06/19/09 The significance of bone marrow cell morphology and its correlation with cytogenetic features in the diagnosis of MDS-RA patients
Leukemia Research, 06/19/09 Cytogenetic evidence of metastatic myxoid liposarcoma and therapy-related myelodysplastic syndrome in a bone marrow biopsy
Human Pathology, 06/19/09 Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended
Current Opinion in Oncology, 06/16/09
|
|
Receive free subspecialty "5-minute updates" via email
|
|
Indexed Journals: Journal of Clinical Oncology, Cancer Research, Annals Oncology
more...
|
187 Available Pages
|
|
